dr. lopes on standard durations of checkpoint inhibition in metastatic lung cancer
Published 4 years ago • 98 plays • Length 1:12Download video MP4
Download video MP3
Similar videos
-
0:56
dr. lopes discusses steroid side effects in lung cancer management
-
1:11
dr. lopes on the rationale to stop immunotherapy after 2 years in lung cancer
-
0:53
the others study: optimal duration of checkpoint inhibitors in solid tumors
-
4:36
efficacy and safety of checkpoint inhibitors in lung cancer
-
6:00
use of immune checkpoint inhibitors for bladder cancer
-
2:23
how long do you continue immune checkpoint inhibitors in metastatic nsclc?
-
44:56
immune checkpoint blockade in cancer therapy
-
26:57
immune checkpoint inhibitors (ici) - and gilvetmab - for treating dog cancer
-
1:02:49
pd-l1/pd-1 cancer immunotherapy and new targets - gordon freeman, phd
-
0:39
dr. lopes on the fda approval of nivolumab/ipilimumab in nsclc
-
1:07
checkpoint inhibitors for lung cancer: combating resistance
-
1:34
dr. wang on the lack of response to checkpoint inhibitors in crc
-
5:56
comparative effectiveness of checkpoint inhibitors in lung cancer
-
1:29
dr. garissino on combinations with immune checkpoint inhibitors in nsclc
-
12:33
introduction: checkpoint inhibition in non-small cell lung cancer
-
0:56
checkpoint inhibitors for lung cancer treatment
-
8:06
lung cancer: clinical insights into key research | gilberto lopes
-
4:47
immune checkpoint inhibitors in small-cell lung cancer
-
1:16
dr. kim on the safety of immune checkpoint inhibition in surgical patients with lung cancer
-
9:04
debate: are we curing metastatic nsclc with immune checkpoint inhibitors? yes - george blumenschein
-
7:22
pd-1 inhibition in lung cancer
-
5:33
cancer immune checkpoint inhibitors